Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)–positive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: von Minckwitz, Gunter, Procter, Marion, de Azambuja, Evandro, Zardavas, Dimitrios, Benyunes, Mark, Viale, Giuseppe, Suter, Thomas, Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Knott, Adam, Lang, Istvan, Levy, Christelle, Yardley, Denise A., Bines, Jose, Gelber, Richard D., Piccart, Martine, Baselga, Jose
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5538020/
https://ncbi.nlm.nih.gov/pubmed/28581356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1703643
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados